Physician profile
Thomas R King
NPI 1639162530
$6,632.68
in general payments reported to CMS, 2019-2025
29 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $724 · 2021: $1,422 · 2022: $1,055 · 2023: $1,127 · 2024: $1,081 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,921.31 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $823.04 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $470.29 | 2019-2022 | |
| Pfizer INC. | $470.14 | 2019-2025 | |
| Amgen INC. | $448.83 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $356.61 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $325.42 | 2019-2024 | Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $296.35 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $232.78 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $201.43 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.83 | 2021-2024 | Jardiance |
| Abiomed | $162.85 | 2020-2024 | Impella |
| Esperion Therapeutics, INC. | $120.63 | 2020-2024 | Nexletol |
| Kestra Medical Technology Services, INC. | $86.23 | 2022-2024 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $69.92 | 2023-2024 | Inpefa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $68.57 | 2023 | Jot Dx |
| Amarin Pharma, INC. | $67.06 | 2020-2021 | |
| Cvrx, INC. | $50.74 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $49.11 | 2019-2020 | |
| Boston Scientific Corporation | $44.17 | 2019-2025 | Watchman Flx |
| Kiniksa Pharmaceuticals, LTD. | $25.85 | 2023 | Arcalyst |
| Philips North America LLC | $23.93 | 2024 | (5091) Amb Mon & Diag Und |
| Inspire Medical Systems, INC. | $21.11 | 2023 | Inspire |
| Irhythm Technologies, INC. | $19.76 | 2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $18.02 | 2023 | |
| Biobeat USA INC. | $17.47 | 2024 | Bb-613 Bpm Kit |
| Impulse Dynamics (USA) INC. | $15.97 | 2024 | Optimizer |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Angiodynamics, INC. | $13.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.